Van Bael & Bellis partners speak on EU competition law developments in the pharmaceutical sector during podcast

04/06/2021
News

Van Bael & Bellis competition partners David Hull and Michael Clancy spoke about recent EU competition law developments in the pharmaceutical sector during a podcast hosted by Wolters Kluwer.

Topics discussed included new competition law developments regarding Covid IP waivers, patent settlements, patent late life cycle strategies, biosimilars, excessive pricing and merger control.

You can listen to the podcast on Wolters Kluwer Competition Law Blog here.

Key contacts

David Hull

Partner Emeritus

T +32 (0)2 647 73 50

E [email protected]
View profile
Michael Clancy

Partner

T +32 (0)2 647 73 50

E [email protected]
View profile

Related practice areas

Search more insights

- 18/02/2025
- News
EU Commission’s first IPI investigation finds unfair treatment for EU medical device makers in China’s procurement market

On 14 January 2025, the European Commission (Commission) published the findings of its first investigation under the International Procurement Instrument (IPI)
Read more
- 07/02/2025
- News
Belgian Competition Authority Launches First Sector Inquiry into Price Revision and Indexation Mechanisms

On 6 Feb 2025, the Belgian Competition Authority (BCA) launched its first sector inquiry and targeted price revision and indexation mechanisms
Read more
- 31/01/2025
- Newsletters
VBB on Competition Law, Volume 2025, No. 1

We are pleased to provide you with the latest issue of our newsletter, VBB on Competition Law, reporting on the major developments in competition law at the European Union, UK and Member State levels.
Read more

Subscribe to our updates

First name *

Last name *

Email *

Company *

Please select the practice areas you are interested in: *

Brexit
Competition
Corporate, Commercial & Regulatory
Diversity & Inclusion
Trade and Customs
Transactions

I have read and accepted Van Bael & Bellis' legal notice *

Insights & news

Van Bael & Bellis partners speak on EU competition law developments in the pharmaceutical sector during podcast

Key contacts

David Hull

Michael Clancy

Related practice areas

Related insights

EU Commission’s first IPI investigation finds unfair treatment for EU medical device makers in China’s procurement market

Belgian Competition Authority Launches First Sector Inquiry into Price Revision and Indexation Mechanisms

VBB on Competition Law, Volume 2025, No. 1